Skip to main content

Table 1 HHT-related and –unrelated clinical characteristics in the 296 patients with hereditary hemorrhagic telangiectasia (HHT), who responded to the SarsCov-2 infection questionnaire

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

General (n = 296)
Age years-old, mean (SD); Range 52.94 (17.59); 3–86
Age class, n (%)  
 < 40 years 55 (18.6)
 40–64 years 158 (53.4)
 ≥ 65 years 83 (28.0)
Gender (Female), n (%) 157 (53.0)
Clinical, HHT-related (n = 296)a
Epistaxis, n (%) 283/296 (95.6)
PAVMs, n (%) 100/279 (35.8)
BAVMs, n (%) 27/235 (11.5)
HAVMs, n (%) 104/275 (37.8)
GI bleeding, n (%) 52/296 (17.6)
Mutated Gene (n = 296)
Identified Mutation, n (%) 236 (79.7)
 ENG 86 (36.5)
 ALK1/ACVRL1 149 (63.1)
 SMAD4 1 (0.4)
Mutation unidentified/Ongoing analysis, n (%) 60 (20.3)
Co-morbidity condition, (n = 296)
Absence of Co-morbidity, n (%) 118 (39.9)
Presence of Co-morbidity, n (%) 178 (60.1)
Diabetes, n (%) 82 (27.7)
Hypertension, n (%) 71 (24.0)
Asthma, n (%) 25 (8.4)
History of Stroke, n (%) 8 (2.7)
Smoking, n (%) 43 (14.5)
Obesity, n (%) 33 (11.1)
Renal Insufficiency, n (%) 6 (2.0)
COPD, n (%) 11 (3.7)
Pulmonary Hypertension, n (%) 5 (1.7)
Oncologic Disease, n (%) 10 (3.4)
Other, n (%) 47 (15.9)
< 3 Co-morbidity conditions, n (%) 137 (46.3)
≥ 3 Co-morbidity conditions, n (%) 41 (13.9)
  1. BAVMs brain arterio-venous malformations, HAVMs hepatic arterio-venous malformations, PAVMs pulmonary arterio-venous malformations
  2. aThe presence of HHT-related visceral arterio-venous malformations was computed by considering only those patients with screening performed in each given organ